Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration

The Journal of Clinical Endocrinology and Metabolism
Louis MaGerald F Watts

Abstract

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein‒like particle containing apolipoprotein(a) [apo(a)]. Patients with elevated Lp(a), even when treated with statins, are at increased risk of cardiovascular disease. We investigated the kinetic basis for elevated Lp(a) in these patients. Apo(a) production rate (PR) and fractional catabolic rate (FCR) were compared between statin-treated patients with and without elevated Lp(a). The kinetics of apo(a) were investigated in 14 patients with elevated Lp(a) and 15 patients with normal Lp(a) levels matched for age, sex, and body mass index using stable isotope techniques and compartmental modeling. All 29 patients were on background statin treatment. Plasma apo(a) concentration was measured using liquid chromatography-mass spectrometry. The plasma concentration and PR of apo(a) were significantly higher in patients with elevated Lp(a) than in patients with normal Lp(a) concentration (all P < 0.01). The FCR of apo(a) was not significantly different between the groups. In univariate analysis, plasma concentration of apo(a) was significantly associated with apo(a) PR in both patient groups (r = 0.699 and r = 0.949, respectively; all P < 0.01). There was no significant association between...Continue Reading

References

May 1, 1983·The Journal of Clinical Investigation·F KremplerF Sandhofer
Mar 1, 1995·The Journal of Clinical Investigation·D J RaderM Grossman
Jun 11, 1998·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·F M RichesG R Thompson
Aug 10, 1999·Diabetologia·S C Riemens, R P Dullaart
May 19, 2000·Scandinavian Journal of Clinical and Laboratory Investigation·S C Riemens, R P Dullaart
Mar 2, 2002·Science·Marie E Csete, John C Doyle
Mar 1, 2005·Metabolism: Clinical and Experimental·Jennifer L JennerErnst J Schaefer
Jun 11, 2009·JAMA : the Journal of the American Medical Association·Pia R KamstrupBørge G Nordestgaard
Jul 6, 2010·Journal of Lipid Research·Stephen J NichollsStanley L Hazen
Oct 23, 2010·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Oct 9, 2012·Metabolism: Clinical and Experimental·Jane Hoover-Plow, Menggui Huang
Oct 27, 2012·Atherosclerosis·Michael E FrischmannHans Dieplinger
Nov 6, 2015·Journal of Lipid Research·Mark J GrahamSotirios Tsimikas
Dec 8, 2015·Journal of Lipid Research·Byambaa EnkhmaaLars Berglund
Mar 16, 2016·Metabolism: Clinical and Experimental·Margaret R DiffenderferErnst J Schaefer
Apr 15, 2016·Journal of Lipid Research·Konrad SchmidtGerd Utermann
Dec 18, 2016·Circulation·Gissette Reyes-SofferHenry N Ginsberg
Jul 20, 2017·Journal of Lipid Research·Gissette Reyes-SofferRajasekhar Ramakrishnan
Jan 13, 2018·Journal of the American College of Cardiology·Sotirios TsimikasLijuan Liu

❮ Previous
Next ❯

Citations

Oct 24, 2019·The Journal of Clinical Endocrinology and Metabolism·Robin P F Dullaart
Apr 30, 2020·Current Opinion in Lipidology·Dick C Chan, Gerald F Watts
Jul 9, 2020·Journal of Clinical Medicine·Maria Francesca GrecoMassimiliano Ruscica

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.